UNSPSC 51141515: Ethotoin

This classification denotes an anticonvulsant agent with the molecular formula C11H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46QG38NC4U, chemically known as 2,4-imidazolidinedione, 3-ethyl-5-phenyl- but generally known as ethotoin, which bears US NIH Compound Identifier 3292. European Medicines Agency schedules Ethotoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07283MIG.

UNSPSC 51141515 Ethotoin, a Commodity code, does not align with the pharmaceutical and drug-management products and services that state and local governments are actually procuring under this classification. The recent solicitations tagged to this code center on naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic pharmaceuticals through cooperative purchasing, none of which concern ethotoin (an anticonvulsant with minimal modern clinical use). The mismatch suggests either a data-entry error in the tagging or a divergence between the code's nominal scope and current purchasing practice.

State and local issuing bodies sourcing under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health facility; the Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026 and an effective contract date of July 1, 2026. Recent activity spans Florida, Texas, and Minnesota, with MMCAP extending purchasing access to participating state and local entities including Oregon. The code shows minimal recent activity specifically aligned to its ethotoin classification and may warrant review for proper UNSPSC assignment if the intent is to track naloxone, generic pharmaceuticals, or prescription-fulfillment program management.